How can we determine whether lenalidomide rechallenge is an option for patients with RRMM?
Prescribing information is available at the top of the page.
Lenalidomide has become an integral part of first-line treatment in patients with multiple myeloma.1 As patients progress to later lines, options can become limited, and the choice of treatment offered in patients who relapse should be carefully evaluated.2 Defining and understanding the lenalidomide status of patients with multiple myeloma can help guide the next line of treatment and which patients can be rechallenged appropriately with lenalidomide post relapse.
Professor Graham Jackson (Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust) discusses this topic in the video above.
We have also developed a summary guide to help determine the lenalidomide status of your patient, this can be accessed below.
Please note, this is to be viewed online only. Not to be downloaded or printed.
If you would like to discuss this content with a Takeda representative, please click here.
NINLARO® (ixazomib) in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.3
NRd, NINLARO + lenalidomide + dexamethasone; RRMM, relapsed/refractory multiple myeloma.
1. Dimopoulos MA et al. Ann Oncol 2021;32:309–322; 2. Botta C et al. Front Oncol 2021;11:64349; 3. NINLARO. Summary of Product Characteristics (Great Britain).
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
